Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCL8 | P10145 | 5/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.49 |
| ▸ | TTR | P02766 | 2/20 | 0.49 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.49 |
| ▸ | UGT1A9 | O60656 | 1/20 | 0.49 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.49 |
| ▸ | ALB | P02768 | 1/20 | 0.49 |
| ▸ | UGT1A6 | P19224 | 1/20 | 0.49 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.49 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.49 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.49 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.49 |
| ▸ | UGT1A7 | Q9HAW7 | 1/20 | 0.49 |
| ▸ | UGT1A10 | Q9HAW8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11317225 | 0.83 | ALDH1A1 (0.50) | RAB9ASMN1; SMN2 | |
| SCHEMBL20369286 | 0.82 | CXCL8 (0.47) | CXCL8PTGS2TTRAKR1B10UGT1A9 | |
| SCHEMBL10878786 | 0.82 | CXCL8 (0.47) | CXCL8PTGS2TTRAKR1B10UGT1A9 | |
| SCHEMBL18484662 | 0.82 | CXCL8 (0.49) | CXCL8PTGS2TTRAKR1B10UGT1A9 | |
| SCHEMBL10108588 | 0.81 | CXCL8 (0.46) | CXCL8PTGS2TTRAKR1B10UGT1A9 | |
| Hydrochloric Acid SCHEMBL10951848 | 0.81 | CXCL8 (0.46) | CXCL8PTGS2TTRAKR1B10UGT1A9 | |
| SCHEMBL25602030 | 0.81 | CXCL8 (0.49) | CXCL8PTGS2TTRAKR1B10UGT1A9 | |
| SCHEMBL11326968 | 0.79 | MAPK1 (0.48) | — | |
| SCHEMBL10802924 | 0.78 | CXCL8 (0.46) | CXCL8PTGS2TTRAKR1B10UGT1A9 | |
| SCHEMBL220500 | 0.78 | CXCL8 (0.46) | CXCL8PTGS2TTRAKR1B10UGT1A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020263888-A1 | CANNABINOID CONJUGATE MOLECULES | DIVERSE BIOTECH, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| US-20180194732-A1 | MULTI-API LOADING PRODRUGS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-07-12 | — | — | US | disclosed |
| US-9938176-B1 | Chloroperoxidase-catalyzed degradation of pharmaceutical pollutants in wastewater | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2018-04-10 | — | — | US | disclosed |
| EP-2655314-B1 | MULTI-API LOADING PRODRUGS | ALKERMES PHARMA IRELAND LTD (IE) | 2018-02-07 | — | — | EP | disclosed |
| US-20160024011-A1 | Multi-API Loading Prodrugs | ALKERMES PHARMA IRELAND LTD (IE) | 2016-01-28 | — | — | US | disclosed |
| US-20120202823-A1 | Multi-API Loading Prodrugs | ALKERMES, INC. | 2012-08-09 | — | — | US | disclosed |
| US-8101782-B2 | Drug hybrid of rivastigmine or physostigmine with tranylcypromine, amoxapine, desipramine, nortriptyline, protriptyline, fluoxetine, fluvoxamine, paroxetine, duloxetine, betahistine, amlodipine, proylhexedrine, rimantadine, desloratadine; Alzheimer's disease; Parkinson's disease, impairment in memory | COLUCID PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20080261950-A1 | Compounds that inhibit cholinesterase | COLUCID PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024011-A1 | Multi-API Loading Prodrugs | AADAC, PAICS, ABCG2 | CXCL8 1892/4885PTGS2 2601/4885TTR 4089/4885 |
| US-20120202823-A1 | Multi-API Loading Prodrugs | AADAC, PAICS, ABCG2 | CXCL8 1892/4885PTGS2 2601/4885TTR 4089/4885 |
| US-20080261950-A1 | Compounds that inhibit cholinesterase | ACHE, BCHE, CHAT | CXCL8 4142/4885PTGS2 1904/4885TTR 3418/4885 |
| US-20180194732-A1 | MULTI-API LOADING PRODRUGS | AADAC, PAICS, ABCG2 | CXCL8 1892/4885PTGS2 2601/4885TTR 4089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.